StreetAlpha
13F holdings · Q3 2026

Versant Venture Management

San Francisco, CA · files as Versant Venture Management, LLC
Know the moment Versant Venture Management filesYou follow Versant Venture Management An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Holdings as of Sep 30, 2026Filed Nov 13, 2026Next filing due Feb 15, 2027CIK 1560009

Versant Venture Management reported 8 stocks worth $109M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are GLUE (34.8%), IPSC (19.1%) and CTNM (15.9%). Compared with Q2 2026, the fund opened new positions in SKYE, added to CTNM and sold out of SKYE.

Latest filing: what Versant Venture Management did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
1 new1 added0 trimmed1 sold outBought about $10.5M · sold about $1.4M
New 1
Added 1
Trimmed 0

None

Sold out 1

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$109M−32.9% vs last quarter
Stocks held81 new · 1 sold out
Top 5 weight91.9%very concentrated
Turnover11%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
GLUE
Monte Rosa Therapeutics Inc
$37.9M34.8%3.2MNo change8 of 8
2
IPSC
Century Therapeutics Inc
$20.8M19.1%12.2MNo change3 of 8
3
CTNM
Contineum Therapeutics Inc
$17.3M15.9%1.3M+750K (+138%)8 of 8
4
JBIO
Jade Biosciences Inc
$13.9M12.8%992KNo change6 of 8
5
LENZ
Lenz Therapeutics Inc
$10.2M9.3%2.7MNo change5 of 8
6
CRSP
Crispr Therapeutics
$8.2M7.5%149KNo change8 of 8
7
SKYE
Skye Bioscience Inc Com
$404K0.4%251KNew position1 of 8
8
TPST
Tempest Therapeutics, Inc.
$225K0.2%270KNo change7 of 8

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
SKYE
Skye Bioscience Inc
$1.4M2M

Reported value

last 8 quarters
$86.7MQ4 '24
$60.2MQ1 '25
$82.1MQ2 '25
$212MQ3 '25
$151MQ4 '25
$141MQ1 '26
$163MQ2 '26
$109MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 13, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Versant Venture Management 13F FAQ

What does Versant Venture Management own?

Versant Venture Management reported 8 stocks worth $109M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are GLUE (34.8%), IPSC (19.1%) and CTNM (15.9%). The table above lists every position in the filing (the top 10 without an account).

What did Versant Venture Management buy and sell in Q3 2026?

Compared with Q2 2026: 1 new positions, 1 added to, 0 trimmed and 1 sold out. New positions include SKYE. It sold all of SKYE.

When will Versant Venture Management file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Versant Venture Management's portfolio worth?

The Q3 2026 filing reports $109M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.